nodes	percent_of_prediction	percent_of_DWPC	metapath
Alendronate—Osteonecrosis of jaw—Sorafenib—thyroid cancer	0.0622	0.104	CcSEcCtD
Alendronate—PTPRE—thyroid gland—thyroid cancer	0.0289	0.0877	CbGeAlD
Alendronate—PTPN4—thyroid gland—thyroid cancer	0.0275	0.0834	CbGeAlD
Alendronate—PTPRE—head—thyroid cancer	0.0257	0.0778	CbGeAlD
Alendronate—Impaired healing—Vandetanib—thyroid cancer	0.0246	0.0412	CcSEcCtD
Alendronate—PTPN4—head—thyroid cancer	0.0244	0.074	CbGeAlD
Alendronate—PTPRS—thyroid gland—thyroid cancer	0.0236	0.0715	CbGeAlD
Alendronate—ATP6V1A—saliva-secreting gland—thyroid cancer	0.0223	0.0676	CbGeAlD
Alendronate—PTPRS—head—thyroid cancer	0.0209	0.0634	CbGeAlD
Alendronate—PTPRE—lymph node—thyroid cancer	0.018	0.0545	CbGeAlD
Alendronate—ATP6V1A—trachea—thyroid cancer	0.0172	0.0521	CbGeAlD
Alendronate—PTPN4—lymph node—thyroid cancer	0.0171	0.0518	CbGeAlD
Alendronate—FDPS—saliva-secreting gland—thyroid cancer	0.0168	0.0509	CbGeAlD
Alendronate—Hypercalcaemia—Vandetanib—thyroid cancer	0.0153	0.0257	CcSEcCtD
Alendronate—PTPRS—lymph node—thyroid cancer	0.0147	0.0444	CbGeAlD
Alendronate—Lymphopenia—Sorafenib—thyroid cancer	0.014	0.0235	CcSEcCtD
Alendronate—ATP6V1A—thyroid gland—thyroid cancer	0.0136	0.0412	CbGeAlD
Alendronate—PTPRS—ECM proteoglycans—LAMA2—thyroid cancer	0.0135	0.221	CbGpPWpGaD
Alendronate—Nephrolithiasis—Vandetanib—thyroid cancer	0.0132	0.0222	CcSEcCtD
Alendronate—FDPS—trachea—thyroid cancer	0.013	0.0393	CbGeAlD
Alendronate—ATP6V1A—head—thyroid cancer	0.0121	0.0366	CbGeAlD
Alendronate—Hypocalcaemia—Vandetanib—thyroid cancer	0.0116	0.0195	CcSEcCtD
Alendronate—FDPS—thyroid gland—thyroid cancer	0.0103	0.0311	CbGeAlD
Alendronate—Leukaemia—Epirubicin—thyroid cancer	0.00984	0.0165	CcSEcCtD
Alendronate—Leukaemia—Doxorubicin—thyroid cancer	0.0091	0.0153	CcSEcCtD
Alendronate—FDPS—head—thyroid cancer	0.00909	0.0276	CbGeAlD
Alendronate—ATP6V1A—lymph node—thyroid cancer	0.00845	0.0256	CbGeAlD
Alendronate—Gastrooesophageal reflux disease—Sorafenib—thyroid cancer	0.00794	0.0133	CcSEcCtD
Alendronate—Hypocalcaemia—Sorafenib—thyroid cancer	0.00783	0.0131	CcSEcCtD
Alendronate—Drug interaction—Sorafenib—thyroid cancer	0.00773	0.013	CcSEcCtD
Alendronate—Oesophageal ulcer—Epirubicin—thyroid cancer	0.00726	0.0122	CcSEcCtD
Alendronate—Dry skin—Vandetanib—thyroid cancer	0.00707	0.0119	CcSEcCtD
Alendronate—Influenza like illness—Sorafenib—thyroid cancer	0.00696	0.0117	CcSEcCtD
Alendronate—Risedronate—PTGS2—thyroid cancer	0.00684	0.529	CrCbGaD
Alendronate—Gastritis—Vandetanib—thyroid cancer	0.00683	0.0115	CcSEcCtD
Alendronate—Oesophageal ulcer—Doxorubicin—thyroid cancer	0.00672	0.0113	CcSEcCtD
Alendronate—Dysphagia—Vandetanib—thyroid cancer	0.00667	0.0112	CcSEcCtD
Alendronate—ATP6V1A—Iron uptake and transport—CP—thyroid cancer	0.00664	0.109	CbGpPWpGaD
Alendronate—Retrosternal pain—Epirubicin—thyroid cancer	0.00658	0.011	CcSEcCtD
Alendronate—FDPS—lymph node—thyroid cancer	0.00637	0.0193	CbGeAlD
Alendronate—Clodronate—PTGS2—thyroid cancer	0.00609	0.471	CrCbGaD
Alendronate—Retrosternal pain—Doxorubicin—thyroid cancer	0.00609	0.0102	CcSEcCtD
Alendronate—Photosensitivity reaction—Vandetanib—thyroid cancer	0.00609	0.0102	CcSEcCtD
Alendronate—Stevens-Johnson syndrome—Vandetanib—thyroid cancer	0.00589	0.00989	CcSEcCtD
Alendronate—Stomatitis—Vandetanib—thyroid cancer	0.00579	0.00972	CcSEcCtD
Alendronate—Haemoglobin—Vandetanib—thyroid cancer	0.00536	0.009	CcSEcCtD
Alendronate—Haemorrhage—Vandetanib—thyroid cancer	0.00534	0.00896	CcSEcCtD
Alendronate—Lymphopenia—Epirubicin—thyroid cancer	0.00518	0.00869	CcSEcCtD
Alendronate—Erythema multiforme—Vandetanib—thyroid cancer	0.00505	0.00847	CcSEcCtD
Alendronate—Lymphopenia—Doxorubicin—thyroid cancer	0.00479	0.00804	CcSEcCtD
Alendronate—Dry skin—Sorafenib—thyroid cancer	0.00477	0.008	CcSEcCtD
Alendronate—Alopecia—Vandetanib—thyroid cancer	0.00472	0.00791	CcSEcCtD
Alendronate—Toxic epidermal necrolysis—Sorafenib—thyroid cancer	0.00469	0.00786	CcSEcCtD
Alendronate—Gastritis—Sorafenib—thyroid cancer	0.00461	0.00773	CcSEcCtD
Alendronate—Gastric ulcer—Epirubicin—thyroid cancer	0.00456	0.00765	CcSEcCtD
Alendronate—Dysgeusia—Vandetanib—thyroid cancer	0.00455	0.00763	CcSEcCtD
Alendronate—Dysphagia—Sorafenib—thyroid cancer	0.0045	0.00755	CcSEcCtD
Alendronate—Muscle spasms—Vandetanib—thyroid cancer	0.00447	0.00749	CcSEcCtD
Alendronate—Transaminases increased—Epirubicin—thyroid cancer	0.00435	0.00731	CcSEcCtD
Alendronate—Abdominal discomfort—Sorafenib—thyroid cancer	0.00431	0.00724	CcSEcCtD
Alendronate—Gastric ulcer—Doxorubicin—thyroid cancer	0.00422	0.00708	CcSEcCtD
Alendronate—Transaminases increased—Doxorubicin—thyroid cancer	0.00403	0.00676	CcSEcCtD
Alendronate—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.00398	0.00667	CcSEcCtD
Alendronate—Chest pain—Vandetanib—thyroid cancer	0.00396	0.00664	CcSEcCtD
Alendronate—Stomatitis—Sorafenib—thyroid cancer	0.00391	0.00656	CcSEcCtD
Alendronate—PTPRS—Extracellular matrix organization—LAMA2—thyroid cancer	0.00384	0.0629	CbGpPWpGaD
Alendronate—Hypercalcaemia—Epirubicin—thyroid cancer	0.00381	0.0064	CcSEcCtD
Alendronate—Infection—Vandetanib—thyroid cancer	0.00377	0.00632	CcSEcCtD
Alendronate—Haemoglobin—Sorafenib—thyroid cancer	0.00362	0.00607	CcSEcCtD
Alendronate—Haemorrhage—Sorafenib—thyroid cancer	0.0036	0.00604	CcSEcCtD
Alendronate—FDPS—Activation of gene expression by SREBF (SREBP)—RXRA—thyroid cancer	0.00354	0.0579	CbGpPWpGaD
Alendronate—Hypercalcaemia—Doxorubicin—thyroid cancer	0.00353	0.00592	CcSEcCtD
Alendronate—PTPRE—IL6-mediated signaling events—AKT1—thyroid cancer	0.00346	0.0567	CbGpPWpGaD
Alendronate—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00345	0.0058	CcSEcCtD
Alendronate—Erythema multiforme—Sorafenib—thyroid cancer	0.0034	0.00571	CcSEcCtD
Alendronate—Dyspepsia—Vandetanib—thyroid cancer	0.00334	0.0056	CcSEcCtD
Alendronate—Pain—Vandetanib—thyroid cancer	0.00324	0.00544	CcSEcCtD
Alendronate—Constipation—Vandetanib—thyroid cancer	0.00324	0.00544	CcSEcCtD
Alendronate—Alopecia—Sorafenib—thyroid cancer	0.00318	0.00534	CcSEcCtD
Alendronate—Erythema—Sorafenib—thyroid cancer	0.00313	0.00526	CcSEcCtD
Alendronate—Gastrointestinal pain—Vandetanib—thyroid cancer	0.0031	0.0052	CcSEcCtD
Alendronate—Dysgeusia—Sorafenib—thyroid cancer	0.00307	0.00515	CcSEcCtD
Alendronate—Muscle spasms—Sorafenib—thyroid cancer	0.00301	0.00506	CcSEcCtD
Alendronate—Body temperature increased—Vandetanib—thyroid cancer	0.003	0.00503	CcSEcCtD
Alendronate—Abdominal pain—Vandetanib—thyroid cancer	0.003	0.00503	CcSEcCtD
Alendronate—Anaemia—Sorafenib—thyroid cancer	0.0029	0.00486	CcSEcCtD
Alendronate—Hypocalcaemia—Epirubicin—thyroid cancer	0.00289	0.00486	CcSEcCtD
Alendronate—Angioedema—Sorafenib—thyroid cancer	0.00286	0.00481	CcSEcCtD
Alendronate—FDPS—Regulation of cholesterol biosynthesis by SREBP (SREBF)—RXRA—thyroid cancer	0.00283	0.0462	CbGpPWpGaD
Alendronate—Ulcer—Epirubicin—thyroid cancer	0.0028	0.0047	CcSEcCtD
Alendronate—Asthenia—Vandetanib—thyroid cancer	0.00272	0.00456	CcSEcCtD
Alendronate—Pruritus—Vandetanib—thyroid cancer	0.00268	0.0045	CcSEcCtD
Alendronate—Musculoskeletal pain—Epirubicin—thyroid cancer	0.00268	0.0045	CcSEcCtD
Alendronate—Hypocalcaemia—Doxorubicin—thyroid cancer	0.00268	0.00449	CcSEcCtD
Alendronate—Myalgia—Sorafenib—thyroid cancer	0.00267	0.00448	CcSEcCtD
Alendronate—Diarrhoea—Vandetanib—thyroid cancer	0.00259	0.00435	CcSEcCtD
Alendronate—Ulcer—Doxorubicin—thyroid cancer	0.00259	0.00435	CcSEcCtD
Alendronate—Melaena—Epirubicin—thyroid cancer	0.00259	0.00434	CcSEcCtD
Alendronate—Influenza like illness—Epirubicin—thyroid cancer	0.00257	0.00432	CcSEcCtD
Alendronate—Infection—Sorafenib—thyroid cancer	0.00254	0.00426	CcSEcCtD
Alendronate—Dizziness—Vandetanib—thyroid cancer	0.00251	0.00421	CcSEcCtD
Alendronate—Musculoskeletal pain—Doxorubicin—thyroid cancer	0.00248	0.00416	CcSEcCtD
Alendronate—Oesophagitis—Epirubicin—thyroid cancer	0.00242	0.00406	CcSEcCtD
Alendronate—Vomiting—Vandetanib—thyroid cancer	0.00241	0.00405	CcSEcCtD
Alendronate—Melaena—Doxorubicin—thyroid cancer	0.00239	0.00402	CcSEcCtD
Alendronate—Rash—Vandetanib—thyroid cancer	0.00239	0.00401	CcSEcCtD
Alendronate—Dermatitis—Vandetanib—thyroid cancer	0.00239	0.00401	CcSEcCtD
Alendronate—Influenza like illness—Doxorubicin—thyroid cancer	0.00238	0.00399	CcSEcCtD
Alendronate—Headache—Vandetanib—thyroid cancer	0.00238	0.00399	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00233	0.00391	CcSEcCtD
Alendronate—Nausea—Vandetanib—thyroid cancer	0.00225	0.00378	CcSEcCtD
Alendronate—Dyspepsia—Sorafenib—thyroid cancer	0.00225	0.00378	CcSEcCtD
Alendronate—Oesophagitis—Doxorubicin—thyroid cancer	0.00224	0.00376	CcSEcCtD
Alendronate—Photosensitivity—Epirubicin—thyroid cancer	0.00219	0.00368	CcSEcCtD
Alendronate—Constipation—Sorafenib—thyroid cancer	0.00219	0.00367	CcSEcCtD
Alendronate—Pain—Sorafenib—thyroid cancer	0.00219	0.00367	CcSEcCtD
Alendronate—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00209	0.00351	CcSEcCtD
Alendronate—ATP6V1A—Signaling by Insulin receptor—CDK1—thyroid cancer	0.00204	0.0333	CbGpPWpGaD
Alendronate—Urticaria—Sorafenib—thyroid cancer	0.00203	0.00341	CcSEcCtD
Alendronate—Photosensitivity—Doxorubicin—thyroid cancer	0.00203	0.0034	CcSEcCtD
Alendronate—Body temperature increased—Sorafenib—thyroid cancer	0.00202	0.00339	CcSEcCtD
Alendronate—Abdominal pain—Sorafenib—thyroid cancer	0.00202	0.00339	CcSEcCtD
Alendronate—Hypersensitivity—Sorafenib—thyroid cancer	0.00188	0.00316	CcSEcCtD
Alendronate—Asthenia—Sorafenib—thyroid cancer	0.00184	0.00308	CcSEcCtD
Alendronate—Pruritus—Sorafenib—thyroid cancer	0.00181	0.00304	CcSEcCtD
Alendronate—Dry skin—Epirubicin—thyroid cancer	0.00176	0.00296	CcSEcCtD
Alendronate—Diarrhoea—Sorafenib—thyroid cancer	0.00175	0.00294	CcSEcCtD
Alendronate—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.00173	0.00291	CcSEcCtD
Alendronate—Gastritis—Epirubicin—thyroid cancer	0.0017	0.00286	CcSEcCtD
Alendronate—Dizziness—Sorafenib—thyroid cancer	0.00169	0.00284	CcSEcCtD
Alendronate—Abdominal distension—Epirubicin—thyroid cancer	0.00167	0.00281	CcSEcCtD
Alendronate—Asthma—Epirubicin—thyroid cancer	0.00166	0.00279	CcSEcCtD
Alendronate—Dysphagia—Epirubicin—thyroid cancer	0.00166	0.00279	CcSEcCtD
Alendronate—Dry skin—Doxorubicin—thyroid cancer	0.00163	0.00274	CcSEcCtD
Alendronate—Vomiting—Sorafenib—thyroid cancer	0.00163	0.00273	CcSEcCtD
Alendronate—Rash—Sorafenib—thyroid cancer	0.00161	0.00271	CcSEcCtD
Alendronate—Dermatitis—Sorafenib—thyroid cancer	0.00161	0.0027	CcSEcCtD
Alendronate—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.0016	0.00269	CcSEcCtD
Alendronate—Headache—Sorafenib—thyroid cancer	0.0016	0.00269	CcSEcCtD
Alendronate—Gastritis—Doxorubicin—thyroid cancer	0.00157	0.00264	CcSEcCtD
Alendronate—Abdominal distension—Doxorubicin—thyroid cancer	0.00155	0.0026	CcSEcCtD
Alendronate—Dysphagia—Doxorubicin—thyroid cancer	0.00154	0.00258	CcSEcCtD
Alendronate—Asthma—Doxorubicin—thyroid cancer	0.00154	0.00258	CcSEcCtD
Alendronate—Nausea—Sorafenib—thyroid cancer	0.00152	0.00255	CcSEcCtD
Alendronate—Photosensitivity reaction—Epirubicin—thyroid cancer	0.00152	0.00255	CcSEcCtD
Alendronate—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.00147	0.00247	CcSEcCtD
Alendronate—FDPS—SREBP signalling—PPARG—thyroid cancer	0.00144	0.0236	CbGpPWpGaD
Alendronate—Stomatitis—Epirubicin—thyroid cancer	0.00144	0.00242	CcSEcCtD
Alendronate—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.0014	0.00236	CcSEcCtD
Alendronate—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.00136	0.00228	CcSEcCtD
Alendronate—Haemoglobin—Epirubicin—thyroid cancer	0.00134	0.00224	CcSEcCtD
Alendronate—Stomatitis—Doxorubicin—thyroid cancer	0.00134	0.00224	CcSEcCtD
Alendronate—Haemorrhage—Epirubicin—thyroid cancer	0.00133	0.00223	CcSEcCtD
Alendronate—Oedema peripheral—Epirubicin—thyroid cancer	0.00131	0.0022	CcSEcCtD
Alendronate—Erythema multiforme—Epirubicin—thyroid cancer	0.00126	0.00211	CcSEcCtD
Alendronate—Haemoglobin—Doxorubicin—thyroid cancer	0.00124	0.00208	CcSEcCtD
Alendronate—Haemorrhage—Doxorubicin—thyroid cancer	0.00123	0.00207	CcSEcCtD
Alendronate—Oedema peripheral—Doxorubicin—thyroid cancer	0.00121	0.00203	CcSEcCtD
Alendronate—Alopecia—Epirubicin—thyroid cancer	0.00118	0.00197	CcSEcCtD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00117	0.0192	CbGpPWpGaD
Alendronate—Erythema multiforme—Doxorubicin—thyroid cancer	0.00116	0.00195	CcSEcCtD
Alendronate—Erythema—Epirubicin—thyroid cancer	0.00116	0.00194	CcSEcCtD
Alendronate—Flatulence—Epirubicin—thyroid cancer	0.00114	0.00192	CcSEcCtD
Alendronate—Dysgeusia—Epirubicin—thyroid cancer	0.00113	0.0019	CcSEcCtD
Alendronate—Muscle spasms—Epirubicin—thyroid cancer	0.00111	0.00187	CcSEcCtD
Alendronate—Alopecia—Doxorubicin—thyroid cancer	0.00109	0.00183	CcSEcCtD
Alendronate—Ill-defined disorder—Epirubicin—thyroid cancer	0.00107	0.0018	CcSEcCtD
Alendronate—Erythema—Doxorubicin—thyroid cancer	0.00107	0.0018	CcSEcCtD
Alendronate—Anaemia—Epirubicin—thyroid cancer	0.00107	0.0018	CcSEcCtD
Alendronate—Flatulence—Doxorubicin—thyroid cancer	0.00106	0.00177	CcSEcCtD
Alendronate—Dysgeusia—Doxorubicin—thyroid cancer	0.00105	0.00176	CcSEcCtD
Alendronate—Malaise—Epirubicin—thyroid cancer	0.00104	0.00175	CcSEcCtD
Alendronate—Vertigo—Epirubicin—thyroid cancer	0.00104	0.00175	CcSEcCtD
Alendronate—Muscle spasms—Doxorubicin—thyroid cancer	0.00103	0.00173	CcSEcCtD
Alendronate—ATP6V1A—Disease—TRIM24—thyroid cancer	0.00103	0.0168	CbGpPWpGaD
Alendronate—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000994	0.00167	CcSEcCtD
Alendronate—Anaemia—Doxorubicin—thyroid cancer	0.00099	0.00166	CcSEcCtD
Alendronate—Chest pain—Epirubicin—thyroid cancer	0.000986	0.00165	CcSEcCtD
Alendronate—Myalgia—Epirubicin—thyroid cancer	0.000986	0.00165	CcSEcCtD
Alendronate—Discomfort—Epirubicin—thyroid cancer	0.000974	0.00163	CcSEcCtD
Alendronate—ATP6V1A—Disease—CHST14—thyroid cancer	0.000967	0.0158	CbGpPWpGaD
Alendronate—Malaise—Doxorubicin—thyroid cancer	0.000966	0.00162	CcSEcCtD
Alendronate—Vertigo—Doxorubicin—thyroid cancer	0.000963	0.00162	CcSEcCtD
Alendronate—Infection—Epirubicin—thyroid cancer	0.000939	0.00158	CcSEcCtD
Alendronate—ATP6V1A—Disease—TRIM33—thyroid cancer	0.000916	0.015	CbGpPWpGaD
Alendronate—Myalgia—Doxorubicin—thyroid cancer	0.000912	0.00153	CcSEcCtD
Alendronate—Chest pain—Doxorubicin—thyroid cancer	0.000912	0.00153	CcSEcCtD
Alendronate—Discomfort—Doxorubicin—thyroid cancer	0.000901	0.00151	CcSEcCtD
Alendronate—Infection—Doxorubicin—thyroid cancer	0.000869	0.00146	CcSEcCtD
Alendronate—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000861	0.00145	CcSEcCtD
Alendronate—Dyspepsia—Epirubicin—thyroid cancer	0.000832	0.0014	CcSEcCtD
Alendronate—FDPS—Metabolism—MINPP1—thyroid cancer	0.00081	0.0132	CbGpPWpGaD
Alendronate—Constipation—Epirubicin—thyroid cancer	0.000808	0.00136	CcSEcCtD
Alendronate—Pain—Epirubicin—thyroid cancer	0.000808	0.00136	CcSEcCtD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—TPR—thyroid cancer	0.0008	0.0131	CbGpPWpGaD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—CP—thyroid cancer	0.0008	0.0131	CbGpPWpGaD
Alendronate—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000797	0.00134	CcSEcCtD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000787	0.0129	CbGpPWpGaD
Alendronate—Feeling abnormal—Epirubicin—thyroid cancer	0.000779	0.00131	CcSEcCtD
Alendronate—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000773	0.0013	CcSEcCtD
Alendronate—Dyspepsia—Doxorubicin—thyroid cancer	0.00077	0.00129	CcSEcCtD
Alendronate—Urticaria—Epirubicin—thyroid cancer	0.000751	0.00126	CcSEcCtD
Alendronate—Constipation—Doxorubicin—thyroid cancer	0.000748	0.00126	CcSEcCtD
Alendronate—Pain—Doxorubicin—thyroid cancer	0.000748	0.00126	CcSEcCtD
Alendronate—Abdominal pain—Epirubicin—thyroid cancer	0.000747	0.00125	CcSEcCtD
Alendronate—Body temperature increased—Epirubicin—thyroid cancer	0.000747	0.00125	CcSEcCtD
Alendronate—ATP6V1A—Signaling by Insulin receptor—NRAS—thyroid cancer	0.00073	0.0119	CbGpPWpGaD
Alendronate—Feeling abnormal—Doxorubicin—thyroid cancer	0.000721	0.00121	CcSEcCtD
Alendronate—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000715	0.0012	CcSEcCtD
Alendronate—Hypersensitivity—Epirubicin—thyroid cancer	0.000696	0.00117	CcSEcCtD
Alendronate—Urticaria—Doxorubicin—thyroid cancer	0.000695	0.00117	CcSEcCtD
Alendronate—Abdominal pain—Doxorubicin—thyroid cancer	0.000691	0.00116	CcSEcCtD
Alendronate—Body temperature increased—Doxorubicin—thyroid cancer	0.000691	0.00116	CcSEcCtD
Alendronate—FDPS—Metabolism—NDUFA13—thyroid cancer	0.000688	0.0113	CbGpPWpGaD
Alendronate—Asthenia—Epirubicin—thyroid cancer	0.000678	0.00114	CcSEcCtD
Alendronate—ATP6V1A—Signaling Pathways—CALCB—thyroid cancer	0.000677	0.0111	CbGpPWpGaD
Alendronate—Pruritus—Epirubicin—thyroid cancer	0.000669	0.00112	CcSEcCtD
Alendronate—FDPS—Metabolism—CHST14—thyroid cancer	0.000647	0.0106	CbGpPWpGaD
Alendronate—Diarrhoea—Epirubicin—thyroid cancer	0.000647	0.00109	CcSEcCtD
Alendronate—Hypersensitivity—Doxorubicin—thyroid cancer	0.000644	0.00108	CcSEcCtD
Alendronate—ATP6V1A—Signaling Pathways—TRIM33—thyroid cancer	0.000642	0.0105	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling by Insulin receptor—KRAS—thyroid cancer	0.000628	0.0103	CbGpPWpGaD
Alendronate—Asthenia—Doxorubicin—thyroid cancer	0.000627	0.00105	CcSEcCtD
Alendronate—Dizziness—Epirubicin—thyroid cancer	0.000625	0.00105	CcSEcCtD
Alendronate—Pruritus—Doxorubicin—thyroid cancer	0.000619	0.00104	CcSEcCtD
Alendronate—ATP6V1A—Disease—TCF7L1—thyroid cancer	0.000611	0.01	CbGpPWpGaD
Alendronate—Vomiting—Epirubicin—thyroid cancer	0.000601	0.00101	CcSEcCtD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000599	0.0098	CbGpPWpGaD
Alendronate—Diarrhoea—Doxorubicin—thyroid cancer	0.000598	0.001	CcSEcCtD
Alendronate—Rash—Epirubicin—thyroid cancer	0.000596	0.001	CcSEcCtD
Alendronate—Dermatitis—Epirubicin—thyroid cancer	0.000595	0.000999	CcSEcCtD
Alendronate—Headache—Epirubicin—thyroid cancer	0.000592	0.000994	CcSEcCtD
Alendronate—Dizziness—Doxorubicin—thyroid cancer	0.000578	0.00097	CcSEcCtD
Alendronate—FDPS—SREBP signalling—AKT1—thyroid cancer	0.000571	0.00935	CbGpPWpGaD
Alendronate—Nausea—Epirubicin—thyroid cancer	0.000561	0.000942	CcSEcCtD
Alendronate—Vomiting—Doxorubicin—thyroid cancer	0.000556	0.000933	CcSEcCtD
Alendronate—Rash—Doxorubicin—thyroid cancer	0.000551	0.000925	CcSEcCtD
Alendronate—Dermatitis—Doxorubicin—thyroid cancer	0.000551	0.000924	CcSEcCtD
Alendronate—Headache—Doxorubicin—thyroid cancer	0.000548	0.000919	CcSEcCtD
Alendronate—ATP6V1A—Signaling by Insulin receptor—HRAS—thyroid cancer	0.000534	0.00874	CbGpPWpGaD
Alendronate—FDPS—Metabolism—HPGD—thyroid cancer	0.000522	0.00854	CbGpPWpGaD
Alendronate—Nausea—Doxorubicin—thyroid cancer	0.000519	0.000872	CcSEcCtD
Alendronate—ATP6V1A—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000503	0.00823	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—TPR—thyroid cancer	0.000448	0.00732	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—PRKAR1A—thyroid cancer	0.00044	0.0072	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—TCF7L1—thyroid cancer	0.000428	0.00701	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000423	0.00692	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—MEN1—thyroid cancer	0.000421	0.00688	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—CALCA—thyroid cancer	0.000335	0.00548	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—TSHR—thyroid cancer	0.000313	0.00513	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PRKAR1A—thyroid cancer	0.000308	0.00504	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—CDK1—thyroid cancer	0.000303	0.00496	CbGpPWpGaD
Alendronate—FDPS—Metabolism—TPR—thyroid cancer	0.0003	0.0049	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PRKAR1A—thyroid cancer	0.000295	0.00482	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—MEN1—thyroid cancer	0.000295	0.00482	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000267	0.00437	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PTCH1—thyroid cancer	0.000266	0.00436	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—SST—thyroid cancer	0.000244	0.00399	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—NRG1—thyroid cancer	0.000243	0.00398	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CALCA—thyroid cancer	0.000235	0.00384	CbGpPWpGaD
Alendronate—FDPS—Metabolism—SLC5A5—thyroid cancer	0.000224	0.00367	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—TERT—thyroid cancer	0.000219	0.00358	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CDK1—thyroid cancer	0.000212	0.00347	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.00021	0.00344	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—HIF1A—thyroid cancer	0.000209	0.00342	CbGpPWpGaD
Alendronate—FDPS—Metabolism—RXRA—thyroid cancer	0.000188	0.00308	CbGpPWpGaD
Alendronate—FDPS—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000183	0.003	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—BRAF—thyroid cancer	0.000173	0.00283	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—NRG1—thyroid cancer	0.00017	0.00279	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—TERT—thyroid cancer	0.000153	0.0025	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—HIF1A—thyroid cancer	0.000146	0.00239	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—PTGS2—thyroid cancer	0.00014	0.00229	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—PTEN—thyroid cancer	0.000122	0.00199	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—BRAF—thyroid cancer	0.000121	0.00198	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PPARG—thyroid cancer	0.000119	0.00195	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—NRAS—thyroid cancer	0.000109	0.00178	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—KRAS—thyroid cancer	9.36e-05	0.00153	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PTGS2—thyroid cancer	9.36e-05	0.00153	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—CCND1—thyroid cancer	8.85e-05	0.00145	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—PTEN—thyroid cancer	8.54e-05	0.0014	CbGpPWpGaD
Alendronate—FDPS—Metabolism—PTEN—thyroid cancer	8.16e-05	0.00134	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—HRAS—thyroid cancer	7.96e-05	0.0013	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—NRAS—thyroid cancer	7.62e-05	0.00125	CbGpPWpGaD
Alendronate—ATP6V1A—Disease—AKT1—thyroid cancer	7.03e-05	0.00115	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—KRAS—thyroid cancer	6.56e-05	0.00107	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—TP53—thyroid cancer	5.83e-05	0.000953	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—HRAS—thyroid cancer	5.57e-05	0.000912	CbGpPWpGaD
Alendronate—ATP6V1A—Signaling Pathways—AKT1—thyroid cancer	4.92e-05	0.000805	CbGpPWpGaD
Alendronate—FDPS—Metabolism—AKT1—thyroid cancer	4.7e-05	0.00077	CbGpPWpGaD
